-
Relative and Fractional Viability in Cancer Assays
2026-09-09
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these metrics capture different combinations of growth inhibition and cell death. The framework improves interpretation of in vitro anticancer responses by aligning endpoint selection with the biological question and by emphasizing response timing.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-09
AZD8055 (SKU A8214) provides a selective ATP-competitive approach for studying mTORC1 and mTORC2 signaling in biochemical and cellular workflows. This guide covers solvent handling, assay controls, pathway verification, and interpretation limits; it is not a clinical efficacy protocol and is unsuitable for water-based formulation without independent validation.
-
AL-8810: Precision FP Receptor Antagonism
2026-09-08
AL-8810 is a selective prostaglandin F2α antagonist for dissecting PTGFR signaling in vascular, smooth muscle, ocular, and endometrial models. This guide translates recent menstrual-like model findings into practical assay strategies centered on receptor-level pharmacology, pathway validation, and orthogonal functional readouts.
-
Phosphatase Inhibitor Cocktail 1: Evidence Guide
2026-09-08
Phosphatase Inhibitor Cocktail 1 is a 100X DMSO-based alkaline phosphatase inhibitor formulation for preserving protein phosphorylation during sample preparation. Its composition supports phosphoproteomic analysis and phospho-signaling assays, but the cited liver-stress study provides biological context rather than direct validation of this reagent.
-
Silymarin: From Flavonolignan Chemistry to Translation
2026-09-07
Silymarin is more than a botanical antioxidant: it is a chemically complex flavonolignan reference material whose value depends on composition-aware assay design, orthogonal validation, and disciplined translational interpretation.
-
In Vitro Activity of Midecamycin: 1983 Findings
2026-09-07
Harold C. Neu’s 1983 study established a comparative in vitro profile for midecamycin, an acetoxy-substituted macrolide antibiotic, across clinically derived Gram-positive and Gram-negative isolates. The work showed useful activity against many streptococci, staphylococci, Haemophilus influenzae, and Listeria, but substantially weaker performance than erythromycin and no meaningful activity against erythromycin-resistant isolates or most tested Enterobacteriaceae and Pseudomonas.
-
Salinomycin Workflow for HCC Research
2026-09-05
Build a reproducible Salinomycin workflow for hepatocellular carcinoma research by combining viability, apoptosis, calcium, transporter, and Wnt/β-catenin readouts. The approach separates practical assay optimization from ionophore-toxicity considerations, helping researchers distinguish pathway-specific effects from nonspecific membrane or vehicle stress.
-
Icatibant in Viral Infections: Evidence and Limits
2026-09-04
The reference letter reframes icatibant as a potential host-directed intervention for hantavirus-associated vascular leakage, while connecting its use to inflammatory and endothelial pathways also discussed in COVID-19. Its main contribution is mechanistic and hypothesis-generating: two severe Puumala hantavirus cases stabilized after treatment, but the uncontrolled evidence cannot establish efficacy or define the optimal treatment window.
-
Grazoprevir Hydrate: HCV Mechanism & Evidence
2026-09-04
Grazoprevir hydrate, also called MK-5172 hydrate, is an oral HCV NS3/4A protease inhibitor that blocks viral polyprotein processing. Clinical evidence supports its use with elbasvir for HCV genotype 1 and 4 infections, including selected patients with HIV/HCV coinfection, compensated cirrhosis, and advanced kidney disease.
-
Indole-3-pyruvic acid in rheumatoid arthritis
2026-09-03
The reference study identifies indole-3-pyruvic acid (IPA) as a potentially protective tryptophan metabolite in rheumatoid arthritis and links its activity to aryl hydrocarbon receptor-dependent restoration of the Th17/Treg balance. By combining patient metabolomics, PBMC differentiation assays, and a collagen-induced arthritis model, the work provides a mechanistic framework for rheumatoid arthritis research while leaving clinical translation unresolved.
-
Catalpol, Glycolysis, and Src Signaling in Liver Fibrosis
2026-09-03
A 2024 Phytomedicine study shows that catalpol suppresses hepatic fibrosis by reducing aerobic glycolysis in activated hepatic stellate cells through an EphA2/FAK/Src signaling axis. Its combination of animal, cellular, target-engagement, and pathway-intervention experiments provides a mechanistic framework for evaluating metabolism-linked antifibrotic strategies.
-
Podophyllotoxin Workflows for Cancer Cell Studies
2026-09-02
Build a reproducible Podophyllotoxin workflow around microtubule disruption, cell-cycle profiling, apoptosis, and autophagy-flux measurements. A recent hepatocellular carcinoma study adds a valuable comparison point by showing why growth inhibition and protective autophagy must be interpreted with orthogonal assays.
-
Bifendate (DDB): From Autophagy Flux to Assay Design
2026-09-02
Bifendate (DDB) is more than a hepatoprotection agent: its effects on autophagy flux, lysosomal function, and lipid droplets create a framework for better liver disease assays. This guide translates mechanistic evidence into practical experimental decisions.
-
CD38 CAR Binder Structures and Affinity Tuning
2026-09-01
The reference study resolves how two CD38-targeting CAR binders, RP02 and 028, use different epitopes and structural mechanisms to influence antigen recognition, enzymatic inhibition, and CAR-T selectivity. Its affinity-attenuated 028R103G design reduced fratricide while preserving cytotoxicity, illustrating how structural information can guide safer CD38-directed cell therapies.
-
Entecavir in Decompensated Chronic Hepatitis B
2026-09-01
Keating’s 2011 review integrates pharmacology, pharmacokinetics, comparative clinical evidence, and tolerability data for Entecavir in chronic hepatitis B with decompensated liver disease. Its principal contribution is a clinically focused interpretation of potent HBV suppression and a high resistance barrier in a population where antiviral choice, renal function, and hepatic reserve strongly influence outcomes.